ADHD Medication in India: Availability and Prescribing Rules

A shorter list than the internet suggests

Adderall (mixed amphetamine salts) and lisdexamfetamine are not currently marketed in India. Rules for carrying any controlled stimulant across a border are separate from market availability, so current CDSCO and Customs requirements should be checked before travelling. Methylphenidate is the only ADHD stimulant currently marketed in India. Atomoxetine is the main non-stimulant alternative, while clonidine may be used in selected adjunct or specialist-led situations.

Indian market check: 27 August 2026. Examples only; no endorsement. This is not an exhaustive list, and availability and pharmacy stock change. Brands with the same generic may differ in strength or release mechanism and may not be interchangeable. Do not switch immediate-release, SR or OD products because a familiar brand is unavailable.

Why the chemist keeps a copy of your prescription

Methylphenidate occupies an unusual legal position in India. It is listed as a psychotropic substance under the Narcotic Drugs and Psychotropic Substances Act 1985, and it is also a Schedule X drug under the Drugs and Cosmetics Rules 1945. Schedule X is the most tightly controlled prescription category in the country.

In practice this means the prescription must be written in duplicate, the pharmacy retains one copy for two years, and the medicine cannot be repeated, refilled or supplied on a telephone request. Only pharmacies holding the relevant licence may stock it. Atomoxetine and clonidine remain prescription medicines, but do not carry methylphenidate’s Schedule X and NDPS controls.

What can and cannot be prescribed by video

This point is frequently misunderstood, and it matters. India’s Telemedicine Practice Guidelines set out a prescription matrix, and anything listed under Schedule X or the NDPS Act sits on the prohibited list. Methylphenidate therefore cannot be prescribed in a teleconsultation at all, whether it is a first appointment or a long-standing follow-up.

Assessment, formulation, second opinions, psychological treatment planning, review of response and monitoring discussions can all take place by video. Non-stimulant options such as atomoxetine are not on the prohibited list. But if a stimulant is the right treatment, an in-person consultation and a physical prescription are required. A service that offers to start you on methylphenidate entirely online is not following Indian rules.

If you are weighing up how much of an assessment can reasonably be done remotely, this article on online adult ADHD assessment in India covers the boundaries in more detail.

What guidance recommends, and what the pharmacy stocks

NICE recommends lisdexamfetamine or methylphenidate as first-line medication for adults, with atomoxetine offered if stimulants cannot be tolerated or if symptoms have not responded to separate six-week trials of both stimulants at an adequate dose. For children aged five and over, methylphenidate is recommended first.

Because lisdexamfetamine is not marketed in India, and guanfacine is not either, Indian practice usually narrows to methylphenidate first and atomoxetine as the main non-stimulant alternative, with clonidine sometimes used as an adjunct. The Indian Psychiatric Society guideline, which sets out titration ranges for methylphenidate, atomoxetine and clonidine, works within the same constraint. This is a constraint of supply, not a judgement that the other medicines are unnecessary.

If your practical choice has narrowed to the two medicines most often discussed for adults here, read the direct comparison of methylphenidate and atomoxetine in India. It explains how onset, monitoring, side effects, comorbidity and prescription rules change the decision.

Medication is also not the automatic first step. NICE recommends medication for adults when significant impairment persists after environmental modifications have been tried and reviewed, and for children aged five and over only when impairment persists despite ADHD-focused support and environmental changes. For children under five, an ADHD-focused group parent-training programme comes first, and medication should not be started without a second specialist opinion.

Short-acting and long-acting solve different problems

Immediate-release methylphenidate typically begins to work within about an hour and wears off over roughly three to four hours, so it usually needs two or three doses a day. It is flexible, it makes the effect easy to observe, and it allows fine adjustment. Its drawbacks are the dosing burden, the mid-afternoon dip some people notice as it wears off, and the difficulty of taking a midday dose discreetly at school or work.

Modified-release preparations aim to cover a working or school day from a single morning dose, with a smoother profile and no midday dose to remember. They are less easily fine-tuned, cost more, and are not always in stock. Atomoxetine works differently again: it is taken daily, and any benefit builds over weeks rather than appearing on the first day, which matters if you are judging whether it is working.

The sensible question is not which formulation is best in the abstract but which hours of your day actually need cover, and what you can reliably take.

Higher is not automatically better

A 2026 dose-effect network meta-analysis in Lancet Psychiatry examined how benefit changes with dose. For methylphenidate, efficacy peaked at around 45 mg a day in children and adolescents. In adults, efficacy continued to increase up to about 50 mg a day, but each further increment added progressively less benefit. Tolerability, meanwhile, worsened as doses climbed.

The practical implication is that the target is the lowest dose producing a real change in how your day works, not the highest dose you can physically tolerate. Doses are individual and are set by the prescribing clinician. Guideline ranges exist, but printing them on a public page invites self-adjustment. With a controlled medicine that is neither safe nor legal.

What should be checked, and how often

Before starting, NICE advises a full assessment including medical history, current medicines, height and weight, baseline pulse and blood pressure, and a cardiovascular assessment. A routine ECG is not required for stimulants, atomoxetine or guanfacine unless there are specific cardiac features in the personal or family history, or another medicine is already raising cardiac risk. Certain findings, such as sudden death in a first-degree relative under 40 suggesting a cardiac cause, fainting on exertion, or a murmur, warrant cardiology review before medication is started.

Side effects, what to report urgently and the questions patients most often ask about the heart and about dependence are covered separately in ADHD medication safety.

Supply, cost and staying legal

Prices are not published here because they move. What is stable is that ADHD medication in India is usually paid for out of pocket, that modified-release products cost considerably more than immediate-release ones, and that brands of the same molecule are not priced alike. Supply is uneven, particularly outside large cities, and a pharmacy that stocked a product last month may not have it this month.

Two practical habits help. Ask your prescriber what to do if the usual product is unavailable, so that you are not improvising at the counter. And do not attempt to source controlled medicines through informal channels, courier them, or carry them across borders without documentation; the legal consequences in India are serious and entirely avoidable.